Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity

Internal Medicine- Japan

doi 10.2169/internalmedicine.2812-19

Full Text

Abstract

Available in

Date

Authors

Publisher

Japanese Society of Internal Medicine

Related search

Pcn17 - Indirect Treatment Comparisons of Nivolumab Versus Regorafenib, Cabozantinib and Best Supportive Care After Treatment With Sorafenib for Hepatocellular Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Sorafenib and Regorafenib in HBV- Or HCV-positive Hepatocellular Carcinoma Patients: Analysis of RESORCE and SHARP Trials

Digestive and Liver Disease
HepatologyGastroenterology
2017English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

A Case of Hepatocellular Carcinoma With Disappearance of Lymph Node Metastasis After Sorafenib Administration

Acta Hepatologica Japonica
Hepatology
2015English

Pcn151 - Cost-Effectiveness Analysis of Regorafenib in the Treatment of Patients With Hepatocelullar Carcinoma Previously Treated With Sorafenib in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Transcatheter Arterial Chemoembolization After Stopping Sorafenib Therapy for Advanced Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2017English

Postsorafenib Systemic Treatments for Hepatocellular Carcinoma: Questions and Opportunities After the Regorafenib Trial

Future Oncology
MedicineCancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy